BioSpace News Archive

iSpecimen Inc. announced the immediate appointment of Tracy Curley as interim CEO, replacing current Chief Executive Officer and President, Christopher Ianelli.

T2 Biosystems, Inc. (NASDAQ:TTOO) today announced the execution of a territory exclusive distribution agreement in the Baltic Region, including Lithuania, Latvia, and Estonia.

Virios Therapeutics, Inc. announced the closing of its previously announced underwritten public offering of 10.0 million shares of its common stock at a public offering price of $0.50 per share, for gross proceeds of $5.0 million, before deducting underwriting discounts, commissions and offering expenses.

Solarvest BioEnergy Inc. (TSXV: SVS) (“Solarvest” or the “Company”) announces that pursuant to the Company’s existing Stock Option Plan, a total of 1,000,000 incentive stock options have been granted to a consultant of the Company

NovaBay® Pharmaceuticals, Inc. announces that Chief Executive Officer Justin Hall has issued the following Letter to Stockholders: To My Fellow Stockholders: Over the past year, we have successfully transformed NovaBay from a single product company into a larger organization with three brands in three distinct market segments.

DENTSPLY SIRONA Inc. announced that Glenn Coleman has been appointed Executive Vice President and Chief Financial Officer, effective September 26, 2022.

Mutations can be good and bad. Sometimes they help an organism adapt and survive.

Ferring Pharmaceuticals today announced that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the U.S. Food and Drug Administration (FDA) issued a positive vote for RBX2660, an investigational microbiota-based live biotherapeutic studied for its potential to reduce recurrence of C. difficile infection (CDI) after antibiotic treatment.

Theralase® Technologies Inc., a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds and their associated drug formulations, used to destroy various cancers, bacteria and viruses, safely and effectively, is pleased to announce that it has closed a non-brokered private placement offering of units.

Aprea Therapeutics, Inc. (Nasdaq: APRE) today announced that the abstract titled “ATRN-W1051, a novel and potent WEE1 inhibitor for the treatment of CCNE1-overexpressing ovarian cancer” will be presented at the 14th Biennial Virtual Ovarian Cancer Research Seminar Series.